drugset / Trial / NCT04927936

A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial

NCT04927936

RandomizedParallel-groupSingle-blindPrevention

Summary

The key objective of the study is to measure the immune response against SARS-CoV-2 after different vaccinations in Health Care Workers (HCW) from 18 to 65 years old vaccinated once with Janssen vaccine. Determination of antibodies by a quantitative immunoglobulin G (IgG) assay (LIAISON SARS-CoV-2 TRIMERICS IgG essay) 28 days after second vaccination (booster) comparing, per protocol, the following three groups: 1. Janssen vaccine/- vs. Janssen vaccine/Janssen vaccine 2. Janssen vaccine/Janssen vaccine vs. Janssen vaccine/Pfizer vaccine 3. Janssen vaccine/Janssen vaccine vs. Janssen vaccine/Moderna vaccine

Timeline

Start
2021-06-25
Primary completion
2022-09
Completion
2022-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ad26.COV2.S Vaccine
Subject BNT162b2 Messenger RNA (mRNA)
Subject Elasomeran Messenger RNA (mRNA)

Indications